Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Novo Nordisk : Awiqli® approved in the USA

    Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes.
  • FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
    FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

    The U.S. Food and Drug Administration today approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). Kresladi is indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant.

  • The Forgotten Half of Diabetic Kidney Disease Finally Gets Its Own Trial and the Results Are Positive
    The Forgotten Half of Diabetic Kidney Disease Finally Gets Its Own Trial and the Results Are Positive

    A phase 3 clinical trial has found that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, produces a significantly greater reduction in a key marker of kidney damage compared to placebo in adults with Type 1 diabetes and chronic kidney disease (CKD). The results were published on March 5, 2026 in the New England Journal of Medicine.

  • After Decades of Waiting, a Lyme Disease Vaccine May Finally Be on the Horizon
    After Decades of Waiting, a Lyme Disease Vaccine May Finally Be on the Horizon

    For anyone who has spent time hiking wooded trails, camping, or simply walking through tall grass, the fear of a tiny tick causing outsized harm is very real. Lyme disease has quietly become one of the most common infectious diseases in the Northern Hemisphere, and yet, for years, doctors have had no vaccine to offer patients. That may be about to change.

    On March 23, 2026, Pfizer and French biotech Valneva announced results from their landmark Phase 3 VALOR trial and the numbers are genuinely encouraging.

  • India's Drug Regulator Gives Conditional Green Light to Zydus's First Human Trial for Chikungunya Vaccine
    India's Drug Regulator Gives Conditional Green Light to Zydus's First Human Trial for Chikungunya Vaccine
    A key advisory body to Indias top drug regulator has approved the first human trial of a homegrown chikungunya vaccine developed by Ahmedabad-based Zydus Lifesciences, but not without strings attached.
  • DTAB Eases Compliance Burden While Tightening Quality Norms Under Revised Schedule M
    DTAB Eases Compliance Burden While Tightening Quality Norms Under Revised Schedule M

    In a balanced move aimed at strengthening drug quality while supporting industry practicality, the Drugs Technical Advisory Board (DTAB) has taken key decisions regarding the implementation of the revised Schedule M during its 93rd meeting.

  • DTAB Backs Major Reform : All Antimicrobials May Soon Be Classified as “New Drugs” in India
    DTAB Backs Major Reform : All Antimicrobials May Soon Be Classified as “New Drugs” in India

    In a significant development for India’s pharmaceutical regulatory landscape, the Drugs Technical Advisory Board (DTAB) has reaffirmed its position to include all antimicrobial drugs under the definition of “New Drugs” as per the New Drugs and Clinical Trials Rules, 2019.

    The decision was taken during the 93rd meeting of DTAB held on February 16, 2026, at FDA Bhawan, New Delhi, conducted in a hybrid format. The board reviewed and approved the Action Taken Report (ATR) from its previous (92nd) meeting held on April 24, 2025.

  • Zydus Lifesciences & Torrent Pharmaceuticals Partner to Co-Market Semaglutide in India
    Zydus Lifesciences & Torrent Pharmaceuticals Partner to Co-Market Semaglutide in India
    Zydus Lifesciences Limited an innovation-led global life-sciences company and Torrent Pharmaceuticals Limited a specialty-focused global pharmaceutical company, have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market.
  • Two-Day International Conference : Pharmacy Beyond Borders : Translating Innovation into Impact for Global Health
    Two-Day International Conference : Pharmacy Beyond Borders : Translating Innovation into Impact for Global Health

    The Himachal Institute of Pharmacy, Paonta Sahib, in association with the Himachal Pradesh State APTI Branch, successfully organized a two-day International Conference on the theme “Pharmacy Beyond Borders: Translating Innovation into Impact for Global Health” on February 27–28, 2026. The event witnessed enthusiastic national and international participation, with more than 1,200 registered delegates representing 22 states and five countries.

  • National Seminar titled Future Pharma Ecosystem – Fostering Synergy among Academia, Industry, Research, Regulatory and Practice
    National Seminar titled Future Pharma Ecosystem – Fostering Synergy among Academia, Industry, Research, Regulatory and Practice

    SIMATS College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (Saveetha University), Chennai, celebrated the National Pharmacy Education Day in accordance with the directions of the Pharmacy Council of India (PCI), held during March 5, 2026 at Kurinji Hall, Saveetha Medical College and Hospital, Chennai. 

Subscribe to Pharma News